Education
About Us
Working with TipRanks
Follow Us
Champions Oncology Inc (CSBR)
NASDAQ:CSBR
CSBR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.60 - $11.99
Previous CloseN/A
Volume27.06K
Average Volume (3M)41.70K
Market Cap
$105.22M
Enterprise Value$161.36M
Total Cash (Recent Filing)$11.64M
Total Debt (Recent Filing)$8.87M
Price to Earnings (P/E)16.9
Beta0.80
Next Earnings
Jul 17, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding13,826,904
10 Day Avg. Volume27,836
30 Day Avg. Volume41,705
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.26
Price to Cash Flow (P/CF)67.60
P/FCF Ratio67.30
Enterprise Value/Market Cap1.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.78
Enterprise Value/Ebitda19.15
Forecast
1Y Price Target
$12.00Price Target Upside57.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Champions Oncology News
PremiumCompany Announcements
Champions Oncology Reports Record Revenue and Strategic Growth
PremiumCompany Announcements
Champions Oncology Achieves Record Revenue and Profit
PremiumCompany Announcements
Champions Oncology Posts Strong Quarterly Revenue Growth---
Ownership Overview
14.20% Insiders
3.02% Mutual Funds
34.48% Other Institutional Investors
45.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CSBR FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was $3.60 and its highest was $11.99 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Champions Oncology Inc’s market cap is $105.22M.
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Jul 17, 2025 which is in 82 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Mar 11, 2025. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.37.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Undervalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate is -0.2.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,826,904 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of $0.36 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in CSBR
---
Champions Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (57.69% Upside)
$12.00 (57.69% Upside)
Blogger Sentiment
Bullish
CSBR Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.29%
12-Months-Change
Fundamentals
Return on Equity
376.84%
Trailing 12-Months
Asset Growth
14.34%
Trailing 12-Months
Company Description
Champions Oncology Inc
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
---
CSBR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected significant positive developments such as record-breaking revenue, successful data licensing, and improved financial metrics. However, challenges in the biotech sector and uncertainties regarding future data revenue contributions were highlighted. Despite the challenges, the company is optimistic about long-term growth.Read More>---
CSBR Stock 12 Month Forecast
Average Price Target
$12.00
▲(57.69% Upside)
Technical Analysis
Tonix Pharma
―
Zentalis Pharmaceuticals
―
C4 Therapeutics
―
Seer
―
Elicio Therapeutics
―
Best Analysts Covering CSBR
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+15.28%
reiterated a buy rating 2 months ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +15.28% per trade.
---